⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL113085 | 0.85 | — | — | |
| SCHEMBL10265108 | 0.79 | — | — | |
| SCHEMBL196024 | 0.78 | — | — | |
| SCHEMBL104786 | 0.78 | — | — | |
| SCHEMBL30350717 | 0.78 | — | — | |
| Hydrochloric Acid SCHEMBL9879440 | 0.76 | KMT2A (0.52) | — | |
| Water SCHEMBL6010194 | 0.76 | POLB (0.50) | — | |
| SCHEMBL91110 | 0.74 | — | — | |
| SCHEMBL13501656 | 0.74 | — | — | |
| SCHEMBL13485361 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 409 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103012278-A | Synthesizing method of 4-chloro-2,6-dimethyl-pyrimidine | CGENETECH SUZHOU CHINA CO LTD | 2013-04-03 | — | — | CN | claimed |
| US-12637426-B2 | 1-cyano-pyrrolidine compounds as USP30 inhibitors | MISSION THERAPEUTICS LIMITED (GB) | 2026-05-26 | — | — | US | disclosed |
| US-20260132147-A1 | BAX INHIBITORS AND USES THEREOF | CASE WESTERN RESERVE UNIV (US) | 2026-05-14 | — | — | US | disclosed |
| US-12479857-B2 | Bax inhibitors and uses thereof | CASE WESTERN RESERVE UNIVERSITY (US) | 2025-11-25 | — | — | US | disclosed |
| US-20250340548-A1 | KRAS G12C INHIBITORS | FRONTIER MEDICINES CORP (US) | 2025-11-06 | — | — | US | disclosed |
| US-12421224-B2 | Azetidinyl O-glycoprotein-2-acetamido-2-deoxy-3-D-glucopyranosidase inhibitors | BIOGEN MA INC. (US) | 2025-09-23 | — | — | US | disclosed |
| US-12378254-B2 | Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2025-08-05 | — | — | US | disclosed |
| US-12291539-B2 | KRAS G12C inhibitors | FRONTIER MEDICINES CORPORATION (US) | 2025-05-06 | — | — | US | disclosed |
| US-20250129103-A1 | METHODS FOR TREATMENT OF CANCER | FRONTIER MEDICINES CORPORATION | 2025-04-24 | — | — | US | disclosed |
| EP-4539840-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | Neuron23, Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| EP-0925286-A1 | SUBSTITUTED PYRIMIDINE DERIVATIVES AND THEIR PHARMACEUTICAL USE | ZENECA LIMITED (GB) | 1999-06-30 | — | — | EP | disclosed |
| EP-0863882-A1 | AMINO SUBSTITUTED PYRIMIDINES AND TRIAZINES | JANSSEN PHARMACEUTICA N.V. (BE) | 1998-09-16 | — | — | EP | disclosed |
| WO-1998021188-A1 | HETEROCYCLE DERIVATIVES WHICH INHIBIT FACTOR Xa | ZENECA LIMITED (GB) | 1998-05-22 | — | — | WO | disclosed |
| WO-1998006705-A1 | SUBSTITUTED PYRIMIDINE DERIVATIVES AND THEIR PHARMACEUTICAL USE | ZENECA LIMITED (GB) | 1998-02-19 | — | — | WO | disclosed |
| WO-1997014684-A1 | AMINO SUBSTITUTED PYRIMIDINES AND TRIAZINES | JANSSEN PHARMACEUTICA N.V. (BE) | 1997-04-24 | — | — | WO | disclosed |
| US-5438058-A | More soluble and less side effects (hypertension) than Minoxidil; treating alopecia, pelade and desquamative dermititis | L'OREAL (FR) | 1995-08-01 | — | — | US | disclosed |
| WO-1995011899-A1 | PYRIMIDINE DERIVATIVES | SHELL INTERNATIONALE RESEARCH MAATSCHAPPIJ B.V. (NL) | 1995-05-04 | — | — | WO | disclosed |
| US-5225555-A | Processes for purification of 2,4-di(1-pyrrolidinyl)-6-chloropyrimidine | THE UPJOHN COMPANY (US) | 1993-07-06 | — | — | US | disclosed |
| US-4215121-A | Pyrazine substituted ureas | MERCK & CO., INC. (US) | 1980-07-29 | — | — | US | disclosed |
| US-4144338-A | N-pyrimidinyl-N-dialkylaminoalkyl ureas | MERCK & CO., INC. (US) | 1979-03-13 | — | — | US | disclosed |